Loading
IARC estimates 2,025 new cancer cases and 679 cancer deaths in Iceland in 2024; the commonest new cancers are breast, prostate and trachea, bronchus and lung. This page is assembled automatically from OnCo's data: 8 trials with a site there, 1 institution and 2 people, and says what OnCo does not yet hold.
| Site | New cases | Rate | OnCo page |
|---|---|---|---|
| Breast | 287 | 93.9 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Prostate | 274 | 72.4 | Prostate cancer |
| Trachea, bronchus and lung | 221 | 28.1 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Colorectum | 213 | 28.6 | Colorectal cancer |
| Bladder | 108 | 13.0 | Bladder & urothelial cancer |
| Kidney | 77 | 11.1 | Renal cell carcinoma |
| Non-Hodgkin lymphoma | 72 | 10.0 | Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma |
| Melanoma of skin | 68 | 11.1 | Melanoma |
| Pancreas | 54 | 7.0 | Pancreatic ductal adenocarcinoma |
| Leukaemia | 49 | 7.7 | Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia |
| Site | Deaths | Rate | OnCo page |
|---|---|---|---|
| Trachea, bronchus and lung | 150 | 17.5 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Prostate | 72 | 14.3 | Prostate cancer |
| Colorectum | 72 | 8.9 | Colorectal cancer |
| Breast | 55 | 15.4 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Pancreas | 49 | 5.8 | Pancreatic ductal adenocarcinoma |
| Liver and intrahepatic bile ducts | 26 | 2.8 | Hepatocellular carcinoma |
| Brain, central nervous system | 26 | 3.6 | Glioma & glioblastoma |
| Leukaemia | 22 | 2.2 | Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia |
| Non-Hodgkin lymphoma | 21 | 2.2 | Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma |
| Oesophagus | 21 | 2.7 | Oesophageal cancer |
| Trial | Lead sponsor | ||||
|---|---|---|---|---|---|
PRECEDE NCT04970056 | Observational study | Recruiting | Arbor Research Collaborative for Health | 60 | 2026-07-22 |
| Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 51 | 2026-09-25 | |
OlympiA NCT02032823 | Phase 3 | Active not recruiting | AstraZeneca | 698 | 2026-07-14 |
iStopMM NCT03327597 | Observational study | Active not recruiting | University of Iceland | 1 | 2025-09-30 |
CARD NCT02485691 | Phase 3 | Completed | Sanofi | 65 | 2022-05-27 |
PROSPECT NCT01322490 | Phase 3 | Completed | Bavarian Nordic | 220 | 2019-09-04 |
| Phase 3 | Completed | Nordic Society for Pediatric Hematology and Oncology | 5 | 2018-09-28 | |
| Phase 3 | Active not recruiting | Oslo University Hospital | 7 | 2017-06-19 |
Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Iceland, captured 2026-10-07 to 2026-10-07. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Iceland is open is on the registry page, under Contacts and Locations.
People whose main affiliation in OnCo is an institution or company in Iceland.
OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. Iceland is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.
Iceland is not among the 60 countries ranked in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.